Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Single-Arm Study of QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer

NCT07283991 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07283991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07283991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Single-Arm Study of QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 30, 2025
Completion date
August 1, 2029
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer